Prostate Cancer - Results from #100

Role of solute carrier transporters SLC25A17 and SLC27A6 in acquired resistance to enzalutamide in castration-resistant prostate cancer. December 27, 2021

Multicenter External Validation of a Nomogram for Predicting Positive Prostate-specific Membrane Antigen/Positron Emission Tomography Scan in Patients with Prostate Cancer Recurrence. December 27, 2021

Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. December 26, 2021

Multi-parametric MRI prostate PIRAD scoring in a district general hospital: Correlating PIRADS 3 results with histological findings. December 24, 2021

Accuracy of fractal analysis and PI-RADS assessment of prostate magnetic resonance imaging for prediction of cancer grade groups: a clinical validation study. December 24, 2021

Mobile Audio Recording Technology to Promote Informed Decision Making in Advanced Prostate Cancer. December 24, 2021

Randomised controlled trial to investigate the effectiveness of the symptom management after radiotherapy (SMaRT) group intervention to ameliorate lower urinary tract symptoms in men treated for prostate cancer. December 24, 2021

Unified model involving genomics, magnetic resonance imaging and prostate-specific antigen density outperforms individual co-variables at predicting biopsy upgrading in patients on active surveillance for low risk prostate cancer. December 24, 2021

How socioeconomic and clinical factors impact prostate-cancer-specific and other-cause mortality in prostate cancer stratified by clinical stage: Competing-risk analysis. December 23, 2021

Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. December 23, 2021

High-Dose-Rate Brachytherapy as Monotherapy for Low- and Intermediate-Risk Prostate Cancer. Oncological Outcomes After a Median 15-Year Follow-Up. December 23, 2021

Patterns of Care and Outcomes for Non-Metastatic Prostate Cancer in the United States: Results of the CancerMPact® Survey 2018. December 23, 2021

An Expert Review on the Combination of Relugolix with Definitive Radiation Therapy for Prostate Cancer. December 23, 2021

Online adaptive radiotherapy potentially reduces toxicity for high-risk prostate cancer treatment. December 22, 2021

Risk of metastatic disease using [18F]PSMA-1007 PET/CT for primary prostate cancer staging. December 22, 2021

How Many Cores Should Be Sampled during Systematic Prostate Biopsy in Case of Negative Multiparametric Magnetic Resonance Imaging? Analysis of 274 Men with Clinical Suspicion of Prostate Cancer. December 22, 2021

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP. December 22, 2021

Current androgen receptor antagonists under investigation for resistant prostate cancer. December 22, 2021

Clinical significance of unfavorable findings in intermediate-risk prostate cancer patients for predicting treatment outcomes after contemporary, dose-escalated multimodal radiotherapy. December 21, 2021

Accuracy of 68Ga-PSMA PET/CT for lymph node and bone primary staging in prostate cancer. December 21, 2021

Page 6 of 1199

email news signup